Expertise in
14
conditions

Dr. Kiran Naqvi

Hematology
UCI Health
101 The City Dr S, 
Orange, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
14
conditions
UCI Health
101 The City Dr S, 
Orange, CA 

Overview

Kiran Naqvi is a Hematologist in Orange, California. Dr. Naqvi is highly rated in 14 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Leukemia, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in MA

Hospital Affiliations

Uci Health-Orange

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UCI Health
101 The City Dr S, Orange, CA 92868
Other Locations
Office
200 S Manchester Ave Ste 300, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Other
Study Drugs: Arsenic Trioxide, Gemtuzumab, Tretinoin
Study Phase: Phase 2
Phase I/II of Venetoclax in Combination With Azacitidine in Treatment Naïve and Relapse Refractory High Risk MDS Individuals
Phase I/II of Venetoclax in Combination With Azacitidine in Treatment Naïve and Relapse Refractory High Risk MDS Individuals
Enrollment Status: Terminated
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Azacitidine, Venetoclax
Study Phase: Phase 1/Phase 2
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: ABL001, Bosutinib
Study Phase: Phase 3
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drugs: Cytarabine, Milademetan Tosylate, Venetoclax
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

73 Total Publications

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.
Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.
Journal: British journal of haematology
Published: August 28, 2025
Similar Doctors
Expertise in
30
conditions
Dr. Lauren Pinter
Hematology
Expertise in
30
conditions
Dr. Lauren Pinter
Hematology

Office

101 The City Dr S Bldg 23, 
Orange, CA 
 (0.8 miles away)
714-456-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lauren Pinter is a Hematologist in Orange, California. Dr. Pinter is highly rated in 30 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Mycosis Fungoides, Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Expertise in
22
conditions
Dr. Stefan Ciurea
Hematology
Expertise in
22
conditions
Dr. Stefan Ciurea
Hematology

UCI Health

101 The City Dr S, 
Orange, CA 
 (0.1 miles away)
714-880-7812
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stefan Ciurea is a Hematologist in Orange, California. Dr. Ciurea is highly rated in 22 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Misako Nagasaka
Hematology
Expertise in
13
conditions
Dr. Misako Nagasaka
Hematology

UCI Health

101 The City Dr S, 
Orange, CA 
 (0.1 miles away)
714-456-7002
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Misako Nagasaka is a Hematologist in Orange, California. Dr. Nagasaka is highly rated in 13 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Gastrostomy.

Frequently Asked Questions about Dr. Kiran Naqvi

How do I make an appointment with Dr. Kiran Naqvi?

You can book an appointment with Dr. Kiran Naqvi by calling their office at 714-456-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kiran Naqvi a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kiran Naqvi is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kiran Naqvi specialize in?

While Dr. Kiran Naqvi is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kiran Naqvi participate in research or clinical trials?

Yes. Dr. Kiran Naqvi has published 73 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Kiran Naqvi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kiran Naqvi accept my insurance?

Dr. Kiran Naqvi accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 714-456-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Naqvi's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile